Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD: Switching to Symtuza in Virologically-suppressed HIV-1
NCT02269917Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of emtricitabine + cobicistat + darunavir + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants With Virologic Rebound (HIV-1 RNA >=50 Copies/mL) Cumulative Through Week 48. Started Mar 2015; status: completed.
02
Drugs
emtricitabine + cobicistat + darunavir + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02269917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02269917.